ArticleCancers2026
Impact of Dermatologic Screening and Methods on Breslow Thickness in Melanoma: A Retrospective Cohort Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cutaneous Squamous Cell Carcinoma Across the Pre-COVID-19, COVID-19 and Post-COVID-19 Eras: Epidemiology, Risk Stratification, Tumour Aggressiveness, and Clinical Outcomes.Dermatopathology (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesMelanoma is the most lethal cutaneous neoplasm, with Breslow thickness being a key prognostic factor. This retrospective cohort study aimed to assess the impact of screening frequency and diagnostic methods on tumour stage at diagnosis and to explore implications for risk-adapted strategies.
methodsBetween 2017 and 2024, 475 cases of melanoma were diagnosed in 397 patients. Screening frequency, diagnostic method, and patient risk were analyzed in relation to tumour stage.
resultsCompared with first-visit cases, patients who underwent screening within two years prior to diagnosis were more often diagnosed with melanoma in situ (32.6% vs. 44-51%;
conclusionsScreening is associated with thinner melanomas and more in situ diagnoses. Digital mole mapping offers additional benefits, with high-risk patients profiting most, while low-risk individuals could be managed with less resource-intensive approaches. These findings support risk-adapted screening strategies focusing on intensive, digitally supported modalities for high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.